Body mass index does not affect the efficacy or bleeding profile during use of an ultra-low-dose combined oral contraceptive.
Impact on hepatic estrogen-sensitive proteins by a 1-year contraceptive vaginal ring delivering Nestorone® and ethinyl estradiol.
17β-Estradiol and natural progesterone for menopausal hormone therapy: REPLENISH phase 3 study design of a combination capsule and evidence review.
A Phase 1 Randomized, Open Label, Rectal Safety, Acceptability, Pharmacokinetic, and Pharmacodynamic Study of Three Formulations of Tenofovir 1% Gel (the CHARM-01 Study).
A Quantitative Multiplex Nuclease Protection Assay Reveals Immunotoxicity Gene Expression Profiles in the Rabbit Model for Vaginal Drug Safety Evaluation.
A review of the endometrial histologic effects of progestins and progesterone receptor modulators in reproductive age women.
Bacterial Vaginosis and Subclinical Markers of Genital Tract Inflammation and Mucosal Immunity.
Biomarkers of Cervical Inflammation and Immunity Associated with Cervical Shedding of HIV-1.
Blocking CXCL9 Decreases HIV-1 Replication and Enhances the Activity of Prophylactic Antiretrovirals in Human Cervical Tissues.
Drospirenone-only oral contraceptive: results from a multicenter noncomparative trial of efficacy, safety and tolerability.
Effect of intravaginal dehydroepiandrosterone (DHEA) on the female sexual function in postmenopausal women: ERC-230 open-label study.
Effect of Intravaginal Prasterone on Sexual Dysfunction in Postmenopausal Women with Vulvovaginal Atrophy.
Enhancing Interferon Regulatory Factor 7 Mediated Antiviral Responses and Decreasing Nuclear Factor Kappa B Expression Limit HIV-1 Replication in Cervical Tissues.
Ethinyl estradiol and levonorgestrel in a transdermal contraceptive delivery system.
Evaluation of the acceptability of intravaginal prasterone ovule administration using an applicator.
Gene Expression Profiling of Human Vaginal Cells In Vitro Discriminates Compounds with Pro-Inflammatory and Mucosa-Altering Properties: Novel Biomarkers for Preclinical Testing of HIV Microbicide Candidates.
Incidence of endometrial spotting or bleeding during continuous-combined estrogen-progestin therapy in postmenopausal women with and without hypertension.
Influence of treatment of vulvovaginal atrophy with intravaginal prasterone on the male partner.
Lack of effect of intravaginal dehydroepiandrosterone (DHEA, prasterone) on the endometrium in postmenopausal women.
Lack of in vitro-in vivo correlation for a UC781-Releasing Vaginal Ring in Macaques.
Multipurpose Prevention Approaches with Antiretroviral-based Formulations.
New contraceptive patch wearability assessed by investigators and participants in a randomized phase 3 study.
Prasterone has parallel beneficial effects on the main symptoms of vulvovaginal atrophy: 52-week open-label study.
Self-reported and verified compliance in a phase 3 clinical trial of a novel low-dose contraceptive patch and pill.
Serum levels of sex steroids and metabolites following 12 weeks of intravaginal 0.50% DHEA administration.
The Contribution of Cervicovaginal Infections to the Immunomodulatory Effects of Hormonal Contraception.
Treatment of pain at sexual activity (dyspareunia) with intravaginal dehydroepiandrosterone (prasterone).
Vaginal atrophy and disease susceptibility: the role of leukocytes.
Vaginal Cytokines Do Not Correlate with Postmenopausal Nulvovaginal Symptoms.
Design, Synthesis, Antiviral Activity, and Pre-Formulation Development of poly-L-arginine-fatty acyl Derivatives of Nucleoside Reverse Transcriptase Inhibitors.